JP6337083B2 - Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療 - Google Patents

Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療 Download PDF

Info

Publication number
JP6337083B2
JP6337083B2 JP2016503092A JP2016503092A JP6337083B2 JP 6337083 B2 JP6337083 B2 JP 6337083B2 JP 2016503092 A JP2016503092 A JP 2016503092A JP 2016503092 A JP2016503092 A JP 2016503092A JP 6337083 B2 JP6337083 B2 JP 6337083B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
chemotherapeutic agent
cancer
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016503092A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016514689A5 (enExample
JP2016514689A (ja
Inventor
ジェイ、コープランド、ストラム
ジョン、エマーソン、ビージ
パトリック、ジョセフ、ロバーツ
フランシス、ハビエル、タバレス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
G1 Therapeutics Inc
Original Assignee
G1 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51527871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6337083(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by G1 Therapeutics Inc filed Critical G1 Therapeutics Inc
Publication of JP2016514689A publication Critical patent/JP2016514689A/ja
Publication of JP2016514689A5 publication Critical patent/JP2016514689A5/ja
Application granted granted Critical
Publication of JP6337083B2 publication Critical patent/JP6337083B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
JP2016503092A 2013-03-15 2014-03-14 Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療 Active JP6337083B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361798772P 2013-03-15 2013-03-15
US61/798,772 2013-03-15
US201361861374P 2013-08-01 2013-08-01
US61/861,374 2013-08-01
US201361911354P 2013-12-03 2013-12-03
US61/911,354 2013-12-03
US201461949786P 2014-03-07 2014-03-07
US61/949,786 2014-03-07
PCT/US2014/029429 WO2014144847A2 (en) 2013-03-15 2014-03-14 Hspc-sparing treatments for rb-positive abnormal cellular proliferation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018089382A Division JP6517401B2 (ja) 2013-03-15 2018-05-07 Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療

Publications (3)

Publication Number Publication Date
JP2016514689A JP2016514689A (ja) 2016-05-23
JP2016514689A5 JP2016514689A5 (enExample) 2017-04-20
JP6337083B2 true JP6337083B2 (ja) 2018-06-06

Family

ID=51527871

Family Applications (9)

Application Number Title Priority Date Filing Date
JP2016503092A Active JP6337083B2 (ja) 2013-03-15 2014-03-14 Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療
JP2016502870A Active JP6430483B2 (ja) 2013-03-15 2014-03-14 化学療法の間の正常細胞の一時的な保護
JP2018089382A Active JP6517401B2 (ja) 2013-03-15 2018-05-07 Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療
JP2018204234A Active JP6767456B2 (ja) 2013-03-15 2018-10-30 化学療法の間の正常細胞の一時的な保護
JP2019077828A Active JP6738933B6 (ja) 2013-03-15 2019-04-16 Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療
JP2020123189A Active JP7250737B2 (ja) 2013-03-15 2020-07-17 Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療
JP2020155691A Active JP7213854B2 (ja) 2013-03-15 2020-09-16 化学療法の間の正常細胞の一時的な保護
JP2023005413A Ceased JP2023052449A (ja) 2013-03-15 2023-01-17 化学療法の間の正常細胞の一時的な保護
JP2023044746A Withdrawn JP2023078341A (ja) 2013-03-15 2023-03-20 Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療

Family Applications After (8)

Application Number Title Priority Date Filing Date
JP2016502870A Active JP6430483B2 (ja) 2013-03-15 2014-03-14 化学療法の間の正常細胞の一時的な保護
JP2018089382A Active JP6517401B2 (ja) 2013-03-15 2018-05-07 Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療
JP2018204234A Active JP6767456B2 (ja) 2013-03-15 2018-10-30 化学療法の間の正常細胞の一時的な保護
JP2019077828A Active JP6738933B6 (ja) 2013-03-15 2019-04-16 Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療
JP2020123189A Active JP7250737B2 (ja) 2013-03-15 2020-07-17 Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療
JP2020155691A Active JP7213854B2 (ja) 2013-03-15 2020-09-16 化学療法の間の正常細胞の一時的な保護
JP2023005413A Ceased JP2023052449A (ja) 2013-03-15 2023-01-17 化学療法の間の正常細胞の一時的な保護
JP2023044746A Withdrawn JP2023078341A (ja) 2013-03-15 2023-03-20 Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療

Country Status (18)

Country Link
US (15) US9527857B2 (enExample)
EP (4) EP2968290B1 (enExample)
JP (9) JP6337083B2 (enExample)
CN (4) CN108283644B (enExample)
CA (2) CA2906166C (enExample)
CY (1) CY1122434T1 (enExample)
DK (1) DK2968290T3 (enExample)
ES (2) ES3032492T3 (enExample)
HR (1) HRP20192168T1 (enExample)
HU (1) HUE046653T2 (enExample)
LT (1) LT2968290T (enExample)
ME (1) ME03557B (enExample)
PL (1) PL2968290T3 (enExample)
PT (1) PT2968290T (enExample)
RS (1) RS59790B1 (enExample)
SI (1) SI2968290T1 (enExample)
SM (1) SMT201900681T1 (enExample)
WO (2) WO2014144847A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020183422A (ja) * 2013-03-15 2020-11-12 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9259399B2 (en) 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
EP3216792B1 (en) 2012-03-29 2020-05-27 G1 Therapeutics, Inc. Lactam kinase inhibitors
CN104302620A (zh) 2012-04-26 2015-01-21 弗朗西斯·泽维尔·塔瓦雷斯 内酰胺的合成
CN105407723A (zh) 2013-03-15 2016-03-16 G1治疗公司 高效的抗赘生剂和抗增生剂
WO2015161285A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
US20160220569A1 (en) * 2015-02-03 2016-08-04 G1 Therapeutics, Inc. CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
CA2989456C (en) * 2015-06-17 2022-01-04 Pfizer Inc. Tricyclic compounds and their use as phosphodiesterase inhibitors
WO2017037575A1 (en) * 2015-08-28 2017-03-09 Novartis Ag A pharmaceutical combination comprising the pi3k inhibitor alpelisib and the cdk4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer
JP6635374B2 (ja) * 2015-12-18 2020-01-22 京都府公立大学法人 癌におけるリン酸化ｒｂタンパク質を指標としたイリノテカン感受性予測法
US11077110B2 (en) * 2016-03-18 2021-08-03 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
EA202092441A1 (ru) 2016-06-07 2021-05-21 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
MX383803B (es) * 2016-07-01 2025-03-14 G1 Therapeutics Inc Sintesis de n-(heteroaril)-pirrolo[3,2-d]pirimidin-2-aminas.
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
CN109789143A (zh) * 2016-07-01 2019-05-21 G1治疗公司 基于嘧啶的抗增殖剂
MX2019002115A (es) 2016-08-23 2019-07-08 Eisai R&D Man Co Ltd Terapias de combinacion para el tratamiento de carcinoma hepatocelular.
EP3538148A1 (en) 2016-11-08 2019-09-18 Dana-Farber Cancer Institute Compositions and methods of modulating anti-tumor immunity
CA3045465A1 (en) 2016-12-05 2018-06-14 G1 Therapeutics, Inc. Preservation of immune response during chemotherapy regimens
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
CN110325191A (zh) 2017-02-22 2019-10-11 G1治疗公司 以较少的副作用治疗egfr-驱动的癌症
SG11201908531WA (en) 2017-03-16 2019-10-30 Eisai R&D Man Co Ltd Combination therapies for the treatment of breast cancer
US10988466B2 (en) 2017-03-23 2021-04-27 Jacobio Pharmaceuticals Co., Ltd. Heterocyclic derivatives useful as SHP2 inhibitors
KR102659211B1 (ko) 2017-06-29 2024-04-18 쥐원 쎄라퓨틱스, 인크. G1t38의 형체 형태 및 그의 제조 방법
JP7233743B2 (ja) 2017-08-11 2023-03-07 晟科薬業（江蘇）有限公司 プロテインキナーゼ阻害剤としての１ｈ－ピラゾロ［４，３－ｈ］キナゾリン系化合物
JP2021509680A (ja) 2018-01-08 2021-04-01 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｇ１ｔ３８の優れた投与レジメン
BR112020015431A2 (pt) 2018-02-15 2020-12-08 Nuvation Bio Inc. Compostos heterocíclicos como inibidores de quinase
AU2019253706A1 (en) * 2018-04-09 2020-11-26 G1 Therapeutics, Inc. Treatment of cancers having driving oncogenic mutations
CA3107750A1 (en) 2018-07-27 2020-01-30 California Institute Of Technology Cdk inhibitors and uses thereof
KR20210049847A (ko) 2018-08-24 2021-05-06 쥐원 쎄라퓨틱스, 인크. 1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
WO2020097625A1 (en) * 2018-11-09 2020-05-14 G1 Therapeutics, Inc. Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/6 inhibitor combinations
WO2020206035A1 (en) * 2019-04-01 2020-10-08 G1 Therapeutics, Inc. Treatment of cdk4/6 inhibitor resistant neoplastic disorders
TW202114684A (zh) * 2019-06-18 2021-04-16 美商G1治療公司 增強癌症病患之抗腫瘤免疫之方法
TW202128174A (zh) * 2019-10-09 2021-08-01 美商G1治療公司 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療
EP4652997A2 (en) * 2020-05-19 2025-11-26 Pharmacosmos Holding A/s Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
BR112022024484A2 (pt) * 2020-06-11 2022-12-27 Lunella Biotech Inc Terapias contra o câncer com o inibidor seletivo de cdk4/6
CN116157403B (zh) * 2020-06-15 2025-04-25 海南先声再明医药股份有限公司 曲拉西利的形态及其制造方法
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
CN113788837B (zh) * 2021-08-02 2022-08-26 深圳湾实验室坪山生物医药研发转化中心 Trilaciclib的合成方法
JP2023148228A (ja) * 2022-03-30 2023-10-13 東芝ライテック株式会社 照明制御装置及び照明制御システム
WO2024073507A1 (en) 2022-09-28 2024-04-04 Theseus Pharmaceuticals, Inc. Macrocyclic compounds and uses thereof
WO2024116069A1 (en) * 2022-11-28 2024-06-06 Assia Chemical Industries Ltd. Novel trilaciclib intermediates, method of preparation and use thereof

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591855A (en) 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
EP0964864B1 (en) 1997-02-05 2008-04-09 Warner-Lambert Company LLC Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US20040006074A1 (en) 1998-04-28 2004-01-08 The Government Of The United States Of America Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer
EP1086105B1 (en) 1998-06-16 2006-03-01 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Fused azepinone cyclin dependent kinase inhibitors
ATE380548T1 (de) 1999-01-29 2007-12-15 Univ Illinois Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
AU6314900A (en) 1999-07-26 2001-02-13 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
US6291504B1 (en) 1999-10-20 2001-09-18 Dupont Pharmaceuticals Company Acylsemicarbazides and their uses
US6867198B2 (en) 1999-12-16 2005-03-15 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
US7053070B2 (en) 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
DK1686130T3 (da) 2000-06-26 2009-04-06 Pfizer Prod Inc Pyrrolo-[2,3-d]-pyrimidinforbindelser som immunsuppressive midler
ES2220811T3 (es) 2000-09-29 2004-12-16 Eli Lilly And Company Procedimiento y compuestos para el tratamiento de enfermedades proliferativas.
AU2002228692A1 (en) 2000-12-01 2002-06-11 Bristol-Myers Squibb Pharma Company 3-(2,4-dimethylthiazol-5-yl) indeno(1,2-c)pyrazol-4-one derivatives as cdk inhibitors
DE60228692D1 (de) 2001-02-28 2008-10-16 Univ Temple Verwendung von alpha, beta ungesättigten arylsulfonen zum schutz von zellen und geweben vor toxizität ionischer strahlung
KR100863624B1 (ko) 2001-05-11 2008-10-15 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Ｃｄ26을 발현하는 세포와 연관된 질환의 치료제로사용되는 항-ｃｄ26 단클론항체
MEP46108A (en) 2002-01-22 2011-02-10 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
CA2495787A1 (en) 2002-05-01 2003-11-13 Chromos Molecular Systems, Inc. Methods for delivering nucleic acid molecules into cells and assessment thereof
EP1590341B1 (en) 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
BRPI0410563B8 (pt) 2003-05-22 2021-05-25 Nerviano Medical Sciences Srl compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas
PT1648889E (pt) 2003-07-11 2008-12-10 Warner Lambert Co Sal isetionato de um inibidor selectivo da cdk4
CA2543308C (en) 2003-10-23 2012-03-06 F. Hoffman-La Roche Ag Triaza-spiropiperidine derivatives for use as glyt-1 inhibitors in the treatment of neurological and neuropsychiatric disorders
GB0327380D0 (en) 2003-11-25 2003-12-31 Cyclacel Ltd Method
BRPI0509580A (pt) 2004-03-30 2007-11-27 Pfizer Prod Inc combinações de inibidores de transdução de sinal
WO2005100999A2 (en) 2004-04-08 2005-10-27 Cornell Research Foundation, Inc. Functional immunohistochemical cell cycle analysis as a prognostic indicator for cancer
ITMI20040874A1 (it) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
WO2005117908A2 (en) 2004-05-28 2005-12-15 Gemin X Biotechnologies, Inc. Triheterocyclic compounds compositions, and methods for treating cancer or viral diseases
ES2411975T3 (es) 2005-01-14 2013-07-09 Janssen Pharmaceutica Nv Pirimidinas heterocíclicas anilladas de 5 miembros como inhibidores de cinasas
BRPI0606319A2 (pt) 2005-01-21 2009-06-16 Astex Therapeutics Ltd compostos farmacêuticos
EP2354139A1 (en) 2005-05-20 2011-08-10 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
EP1779848A1 (en) 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
US7579351B2 (en) 2005-12-09 2009-08-25 Hoffmann-La Roche Inc. Tricyclic amide derivatives
JP2009524589A (ja) 2005-12-22 2009-07-02 ワイス 置換されたイソキノリン−１，３（２ｈ，４ｈ）−ジオン、１−チオキソ−１，４−ジヒドロ−２ｈ−イソキノリン−３−オン誘導体、および１，４−ジヒドロ−３（２ｈ）−イソキノロン、ならびにキナーゼインヒビターとしてのそれらの使用
CN101415409B (zh) 2006-04-05 2012-12-05 诺瓦提斯公司 用于治疗癌症的治疗剂的组合
US20070270362A1 (en) 2006-05-18 2007-11-22 The University Of Washington Methods and compositions for prevention or treatment of inflammatory-related diseases and disorders
US8222256B2 (en) 2006-07-05 2012-07-17 Exelixis, Inc. Methods of using IGFIR and ABL kinase modulators
CA2662587C (en) 2006-09-11 2013-08-06 Curis, Inc. Quinazoline based egfr inhibitors
JP2010513317A (ja) 2006-12-14 2010-04-30 パナシー ファーマシューティカルズ インコーポレーティッド サイクリン依存性キナーゼの阻害による神経保護方法
KR20090091306A (ko) 2006-12-22 2009-08-27 노파르티스 아게 암, 염증 및 바이러스 감염 치료용 ｃｄｋ 억제제로서의 헤테로아릴-헤테로아릴 화합물
CA2690748A1 (en) 2007-06-25 2008-12-31 Neurogen Corporation Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
US9259399B2 (en) 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
WO2009085185A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
JP5579715B2 (ja) 2008-07-29 2014-08-27 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ
US8685980B2 (en) 2008-08-22 2014-04-01 Novartis Ag Pyrrolopyrimidine compounds and their uses
CA2738925A1 (en) * 2008-10-01 2010-04-08 The University Of North Carolina At Chapel Hill Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
WO2010051127A2 (en) 2008-10-01 2010-05-06 The University Of North Carolina At Chapel Hill Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
WO2010132725A2 (en) * 2009-05-13 2010-11-18 The University Of North Carolina At Chapel Hill Cyclin dependent kinase inhibitors and methods of use
US9040519B2 (en) 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
FR2957748B1 (fr) * 2010-03-16 2012-09-07 St Microelectronics Grenoble 2 Composant electronique a montage en surface
CN102299073A (zh) 2010-06-25 2011-12-28 无锡华润上华半导体有限公司 Vdmos器件及其制作方法
US8691830B2 (en) * 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
EP2632467B1 (en) * 2010-10-25 2016-06-22 G1 Therapeutics, Inc. Cdk inhibitors
AU2011323455B2 (en) 2010-11-02 2017-07-27 Promega Corporation Coelenterazine derivatives and methods of using same
CN103501789A (zh) 2010-11-17 2014-01-08 北卡罗来纳大学查珀尔希尔分校 通过抑制增殖性激酶cdk4和cdk6保护肾组织免于局部缺血
HUE024504T2 (en) 2010-12-23 2016-01-28 Sanofi Sa Pyrimidine derivatives, a process for their preparation and their use in medicine
WO2012129344A1 (en) 2011-03-23 2012-09-27 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
BR112013033940A2 (pt) 2011-07-01 2017-02-14 Novartis Ag terapia combinada compreendendo um inibidor de cdk4/6 e um inibidor de pi3k para uso no tratamento de câncer
JP5427321B2 (ja) 2011-07-27 2014-02-26 アストラゼネカ アクチボラグ ２−（２，４，５−置換−アニリノ）ピリミジン化合物
EP3216792B1 (en) 2012-03-29 2020-05-27 G1 Therapeutics, Inc. Lactam kinase inhibitors
CN104302620A (zh) 2012-04-26 2015-01-21 弗朗西斯·泽维尔·塔瓦雷斯 内酰胺的合成
EP2880448B1 (en) 2012-08-03 2022-06-29 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
US9241941B2 (en) 2012-09-20 2016-01-26 Memorial Sloan-Kettering Cancer Center Methods for treatment of lymphomas with mutations in cell cycle genes
RU2015125307A (ru) 2012-11-28 2017-01-10 Новартис Аг Комбинированная терапия
WO2014144847A2 (en) * 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Hspc-sparing treatments for rb-positive abnormal cellular proliferation
CN105407723A (zh) * 2013-03-15 2016-03-16 G1治疗公司 高效的抗赘生剂和抗增生剂
US20140274896A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
BR112015025711A8 (pt) 2013-04-08 2019-12-17 Janssen Pharmaceutica Nv uso de ibrutinibe e coposição farmacêutica compreendendo ibrutinibe e um agente anticâncer
SG10201709926VA (en) 2013-05-30 2017-12-28 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
US20160257688A1 (en) 2013-10-24 2016-09-08 Francis Xavier Tavares Process for Synthesis of Lactams
US10314842B2 (en) 2013-12-02 2019-06-11 Cornell University Methods for treating B cell proliferative disorders
PL3091008T3 (pl) 2013-12-31 2018-12-31 Xuanzhu Pharma Co., Ltd. Inhibitor kinazy i jego zastosowanie
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2015161285A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation
EP3191098A4 (en) * 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
US9374037B2 (en) 2014-10-30 2016-06-21 M/A-Com Technology Solutions Holdings, Inc. Voltage-controlled oscillator with mask-selectable performance
US20160220569A1 (en) 2015-02-03 2016-08-04 G1 Therapeutics, Inc. CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
MX383803B (es) * 2016-07-01 2025-03-14 G1 Therapeutics Inc Sintesis de n-(heteroaril)-pirrolo[3,2-d]pirimidin-2-aminas.
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
CA3045465A1 (en) * 2016-12-05 2018-06-14 G1 Therapeutics, Inc. Preservation of immune response during chemotherapy regimens
CN110267659A (zh) * 2016-12-08 2019-09-20 西奈山伊坎医学院 用于治疗cdk4/6介导的癌症的组合物和方法
MX2019008158A (es) * 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
US11395821B2 (en) * 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
US10208011B2 (en) * 2017-02-10 2019-02-19 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
CN110325191A (zh) * 2017-02-22 2019-10-11 G1治疗公司 以较少的副作用治疗egfr-驱动的癌症
KR102659211B1 (ko) * 2017-06-29 2024-04-18 쥐원 쎄라퓨틱스, 인크. G1t38의 형체 형태 및 그의 제조 방법
WO2019136244A1 (en) 2018-01-04 2019-07-11 G1 Therapeutics, Inc. Heterocyclic compounds for the treatment of abnormal cellular proliferation
JP2021509680A (ja) * 2018-01-08 2021-04-01 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｇ１ｔ３８の優れた投与レジメン
AU2019253706A1 (en) * 2018-04-09 2020-11-26 G1 Therapeutics, Inc. Treatment of cancers having driving oncogenic mutations
WO2020023502A1 (en) * 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
TW202114684A (zh) * 2019-06-18 2021-04-16 美商G1治療公司 增強癌症病患之抗腫瘤免疫之方法
TW202128174A (zh) * 2019-10-09 2021-08-01 美商G1治療公司 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020183422A (ja) * 2013-03-15 2020-11-12 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療
JP7250737B2 (ja) 2013-03-15 2023-04-03 ジー１、セラピューティクス、インコーポレイテッド Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療

Also Published As

Publication number Publication date
US11717523B2 (en) 2023-08-08
CN105473140A (zh) 2016-04-06
ES3032492T3 (en) 2025-07-21
CA2906156A1 (en) 2014-09-18
EP2968291A4 (en) 2016-09-28
PT2968290T (pt) 2019-11-27
US9487530B2 (en) 2016-11-08
US20200345742A1 (en) 2020-11-05
US20180360841A1 (en) 2018-12-20
US9464092B2 (en) 2016-10-11
DK2968290T3 (da) 2019-11-25
US20170037051A1 (en) 2017-02-09
US10434104B2 (en) 2019-10-08
US20170100405A1 (en) 2017-04-13
EP2968291C0 (en) 2025-04-16
JP7250737B2 (ja) 2023-04-03
PL2968290T3 (pl) 2020-04-30
US20170065597A1 (en) 2017-03-09
US9931345B2 (en) 2018-04-03
HK1223293A1 (zh) 2017-07-28
WO2014144847A2 (en) 2014-09-18
CN108434149B (zh) 2021-05-28
WO2014144847A3 (en) 2015-07-02
LT2968290T (lt) 2019-12-10
JP6738933B2 (ja) 2020-08-12
US10925878B2 (en) 2021-02-23
CN105473140B (zh) 2018-04-10
US20180360840A1 (en) 2018-12-20
CN108283644A (zh) 2018-07-17
US10076523B2 (en) 2018-09-18
CN108434149A (zh) 2018-08-24
JP6517401B2 (ja) 2019-05-22
US11654148B2 (en) 2023-05-23
EP4596051A3 (en) 2025-10-29
SI2968290T1 (sl) 2020-02-28
JP2016513737A (ja) 2016-05-16
EP2968290B1 (en) 2019-09-25
JP2019055954A (ja) 2019-04-11
ME03557B (me) 2020-07-20
JP6767456B2 (ja) 2020-10-14
HRP20192168T1 (hr) 2020-02-21
US20180221378A1 (en) 2018-08-09
JP2023052449A (ja) 2023-04-11
JP6738933B6 (ja) 2020-09-09
EP2968290A4 (en) 2016-09-28
JP2018150333A (ja) 2018-09-27
HUE046653T2 (hu) 2020-03-30
US20140275067A1 (en) 2014-09-18
EP4596051A2 (en) 2025-08-06
US20190070185A1 (en) 2019-03-07
CA2906166C (en) 2023-03-14
CN108283644B (zh) 2022-03-18
EP2968290A1 (en) 2016-01-20
US20230381189A1 (en) 2023-11-30
US10966984B2 (en) 2021-04-06
US20210213022A1 (en) 2021-07-15
US20140271466A1 (en) 2014-09-18
SMT201900681T1 (it) 2020-01-14
CA2906166A1 (en) 2014-09-18
CN105407889B (zh) 2018-06-01
WO2014144326A1 (en) 2014-09-18
EP2968291A2 (en) 2016-01-20
JP2020183422A (ja) 2020-11-12
US11040042B2 (en) 2021-06-22
US20210299130A1 (en) 2021-09-30
RS59790B1 (sr) 2020-02-28
ES2761406T3 (es) 2020-05-19
JP7213854B2 (ja) 2023-01-27
HK1222792A1 (zh) 2017-07-14
JP2021001197A (ja) 2021-01-07
US20140275066A1 (en) 2014-09-18
US9527857B2 (en) 2016-12-27
US10660896B2 (en) 2020-05-26
JP2023078341A (ja) 2023-06-06
US20230364098A1 (en) 2023-11-16
EP2968291B1 (en) 2025-04-16
JP2016514689A (ja) 2016-05-23
HK1258477A1 (zh) 2019-11-15
EP3653209A1 (en) 2020-05-20
CY1122434T1 (el) 2021-01-27
JP6430483B2 (ja) 2018-11-28
CN105407889A (zh) 2016-03-16
CA2906156C (en) 2023-03-14
US10085992B2 (en) 2018-10-02
JP2019131609A (ja) 2019-08-08

Similar Documents

Publication Publication Date Title
JP6738933B2 (ja) Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療
US20230241059A1 (en) Anti-neoplastic combinations and dosing regimens using cdk4/6 inhibitor compounds to treat rb-positive tumors
US12285431B2 (en) Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
HK1260112A1 (en) Hspc-sparing treatments for rb-positive abnormal cellular proliferation
HK1260112B (en) Hspc-sparing treatments for rb-positive abnormal cellular proliferation
HK1222792B (en) Hspc-sparing treatments for rb-positive abnormal cellular proliferation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180319

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180403

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180507

R150 Certificate of patent or registration of utility model

Ref document number: 6337083

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

Free format text: JAPANESE INTERMEDIATE CODE: R313113